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Abstract Using alternative splicing reporters we have pre-
viously observed mesenchymal epithelial transitions in
Dunning AT3 rat prostate tumors. We demonstrate here that
the Dunning DT and AT3 cells, which express epithelial and
mesenchymal markers, respectively, represent an excellent
model to study epithelial transitions since these cells recapit-
ulategeneexpressionproﬁlesobservedduringhumanprostate
cancer progression. In this manuscript we also present the
developmentoftwonewtoolstostudytheepithelialtransitions
by imaging alternative splicing decisions: a bichromatic ﬂuo-
rescence reporter to evaluate epithelial transitions in culture
and in vivo, and a luciferase reporter to visualize the distri-
bution of mesenchymal epithelial transitions in vivo.
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Introduction
Examination of the human genome reveals a preponder-
ance of complex genes that produce equally intricate
primary transcripts [1–3]. In humans, a typical pre-mes-
senger RNA (pre-mRNA) contains seven or eight introns,
each averaging more than 3,000 nucleotides in length, and
eight or nine exons, which average only 300 nucleotides,
with the average internal exon measuring only 145 nucle-
otides [1, 2]. Components of the spliceosome (U snRNPs
and general splicing factors) recognize intronic and exonic
sequence elements that critically deﬁne exon–intron
boundaries and mediate the removal of introns and ligation
of exons in the process known as pre-mRNA splicing.
Alternative RNA splicing is the process by which a pri-
mary transcript yields different mature RNAs leading to the
production of protein isoforms with diverse and even
antagonistic functions [4–9]. The annotation of mammalian
genomes reveals that the bulk of intron-containing tran-
scripts are alternatively spliced [10–13]. Many different
forms of alternative splicing together with differential use
of promoters and 30 cleavage/polyA sites leads to stag-
gering versatility among transcripts driven by RNAP II.
Most importantly, alternative splicing is one of the several
mechanisms by which broad programs of gene expression
are established in different cell types.
Anelegantexampleofregulatedalternativesplicingisthe
choicebetweenIIIbandIIIcisoformsofFGFR2.Alternative
inclusion of exon 8 (IIIb) or exon 9 (IIIc) leads to the
expression of FGFR2(IIIb) and FGFR2(IIIc), respectively.
This decision is cell-type speciﬁc, most epithelial cells
express the FGFR2(IIIb) isoform exclusively, and most
mesenchymal cells express solely FGFR2(IIIc). The alter-
native use of exons IIIb or IIIc alters ligand binding [14, 15]
anditsregulationisrequiredfornormaldevelopmentinmice
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splicing depends on the interplay between several cis-acting
elements in the FGFR2 pre-mRNA and trans-acting factors,
some of which are cell-type speciﬁc. Two cell-type speciﬁc
cis-acting elements, intronic activating sequence 2 (IAS2)
and intronic splicing activator and repressor (ISAR, also
known as IAS3), which form a stem, collaborate to activate
exon IIIb and repress exon IIIc in an epithelial-speciﬁc
manner [19–23]. Additionally, we identiﬁed two gcaug
sequence elements, located downstream of ISAR and within
exonIIIc,andshowedthattheseplayaroleinepithelialexon
IIIc repression [22]. Moreover, we showed that splicing
factors of the Fox family of proteins are responsible for this
repression of exon IIIc in epithelial cells [24]. The Fox
family of proteins, and in particular Fox-2, is a likely can-
didate for a master regulator of FGFR2 splicing during
epithelial plasticity.
The differential splicing of FGFR2 transcripts under-
scores large differences in gene expression programs in
epithelial and mesenchymal cells. Epithelial cells are
tightly connected to each other by specialized structures on
their surface and form well organized apical-basal polar-
ized layers [25]. Mesenchymal cells, on the other hand, do
not form well-organized layers, are motile, and have a
front-back polarity. Epithelial cells can become mesen-
chymal cells and vice versa via phenotypic transitions,
known as epithelial–mesenchymal (EMT) and mesenchy-
mal–epithelial transitions (MET). These are critical for
vertebrate ontogeny and have been proposed to play
important roles in tumorigenesis [25–28]. Indeed, the evi-
dence that these epithelial transitions are seen in prostate
cancer is now overwhelming, and the data that support
their importance are compelling [29–32].
In this manuscript we build upon our previous obser-
vation that cells in Dunning AT3 rat prostate tumors show
heterogeneity in the alternative splicing of FGFR2 tran-
scripts and this is due to MET [29]. We demonstrate here
that the Dunning DT and AT3 cells, which express epi-
thelial and mesenchymal markers, respectively, represent
an excellent model to study epithelial transitions in prostate
cancer. Moreover, we introduce two new tools to study the
epithelial transitions by imaging alternative splicing deci-
sions: a bichromatic ﬂuorescence reporter to evaluate
epithelial transitions in culture and in vivo, and a luciferase
reporter to visualize the distribution of MET in vivo.
Materials and methods
Gene expression analysis
Triplicate cultures of AT3 and DT cells were grown to *
60% conﬂuency. Total RNA was isolated using the RNeasy
kit (Qiagen, Inc.) and triplicate samples were submitted to
the Duke Microarray Facility. Gene expression analysis was
performed using the RO27 K rat spotted arrays 3.0 (Operon,
Inc.). Bioinformatical analysis of expression differences
between AT3 and DT cells was done using the GeneSpring
GXsoftwareversion 7.3.1(AgilentTechnologies,Inc.).The
data ﬁles (representing signals for 26,986 gene probes in all
six data points, three for AT3 and three for DT) were nor-
malized using the feature: per Spot and per Chip—intensity
dependent (lowess) normalization. The resulting gene list
was used to determine the signiﬁcantly differentially
expressed genes between AT3 and DT using the ‘‘Filtering
on Volcano plot’’ feature with the following characteristics:
(1) Test type: parametric test, don’t assume variances equal;
(2)Multiple testing correction:none; (3)FoldDifference:2-
fold or greater and a P-value cutoff of 0.01.
Gene set enrichment analysis
To infer differential pathway activity from gene expression
differences between the AT3 and DT cells, gene set anal-
ysis was performed (GSEA) [33]. Brieﬂy, we ﬁrst
generated a gene set from microarray features from the
R027 K rat spotted array (v 3.0) with increased expression
in the AT-3 cells compared to the DT cells using an a priori
established cut off of C2-fold increase in average expres-
sion. The features identiﬁed using the rat array were
mapped to Affymetrix U133A accession numbers using
annotation ﬁles provided by Operon (See Supplemental
Table 1). Differential enrichment of this gene set was then
tested across a cohort of local (n = 16) and metastatic (n =
32) prostate cancer tumors using previously published data
[34]. The statistical signiﬁcance of differential enrichment
in one class (metastatic) vs. the other (local) was deter-
mined using a weighted Kolmogorov–Smirnoff metric to
determine an enrichment score (ES), and random permu-
tation of phenotypic labels was performed to compare the
observed results with reiterative random permutations of
class labels to establish a false discovery rate (FDR).
Parameters for GSEA included: (1) genes were ranked
according differential expression between metastatic (up)
and local (down) prostate samples using a Student’s t-test,
(2) weighted analysis was performed with the weight
assigned a value of 1.0, and (3) 1,000 random permutations
of randomized class labels were used to establish the FDR.
Bichromatic ﬂuorescent reporter pRGIIIc
The minigene pRGIIIc was constructed on the backbone of
minigene RG6 [35] kindly provided by Dr Thomas Cooper
(Baylor College of Medicine). The exon IIIc and ﬂanking
intronic regions of the FGFR2 gene were ampliﬁed from the
pRIIIcI
2 minigene [29] and inserted between the XbaI and
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encoding a nuclear localization signal in the ﬁrst exon of the
RG6 minigene was deleted. Complete sequence of the
plasmid will be provided upon request. AT3 and DT rat
prostate tumor cells were kindly provided to our laboratory
by Dr. Wallace McKeehan (Texas A&M University Health
Sciences Center, Houston, TX). Cells were transfected
using lipofectamine (Invitrogen Corporation, Inc.) and
stable transfectants were selected using 500 lg/ml G418.
Luciferase reporters
The minigenes pFFint and pFFIIIcI
2 are identical to pRint
and pRIIIcI
2 (described elsewhere [29]) except for having
the ﬁreﬂy luciferase ORF instead of the RFP ORF. Com-
plete sequence of the plasmids will be provided upon
request. AT3 cells were transfected using lipofectamine
(Invitrogen Corporation) and stable transfectants were
selected using 15 lg/ml blasticidin.
Animals and tumor cells implantation
AT3 cells were trypsinized, resuspended in PBS to a ﬁnal
concentration of 10
6/ml and kept on ice. 3 9 10
5 cells were
injected subcutis (sc) in the ﬂanks of Copenhagen 2331
rats (Harlan, Inc.) (75-90 g and *2 months in age).
Animals were continuously monitored for tumor growth.
All animal procedures were performed according to the
Duke University Institutional and Animal Care and Use
guidelines.
Bioluminescence imaging
For cell culture studies D-luciferin was added to the culture
medium (ﬁnal concentration 50 lg/ml) and 10 min later
imaging was performed using the IVIS imaging system
(Xenogen). For animal in vivo imaging, following anaes-
thesia, rats were injected intraperitonealy with D-luciferin
(50 mg/kg) and 10 min later sequential imaging was per-
formed as described.
Results and discussion
The Dunning DT and AT3 cell lines as a model to study
epithelial transitions in prostate cancer
We have previously studied the alternative splicing of
FGFR2 transcripts in DT (aka DT3) and AT3 cells, which
are two cell lines derived from the well-differentiated and
androgen sensitive Dunning R-3327 rat prostate tumor [36–
40]. The indolent DT tumor cells express FGFR2(IIIb) like
normal prostate epithelium, while AT3 cells have switched
to the FGFR2(IIIc) isoform [38]. The signiﬁcance of these
alternative decisions for tumor behavior is underscored by
the fact that forced expression of FGFR2(IIIb) suppresses
tumor progression of AT3 tumors [41]. More recently, we
have developed ﬂuorescence reporters that permit us to
image FGFR2 alternative splicing decisions in culture and
in vivo (in normal tissues and tumors) [29, 42, 43]. Our
data suggested that the DT and AT3 cells could be a useful
system to evaluate epithelial transitions in the context of
prostate cancer, with the latter being the result of a prior
EMT. Indeed, DT cells expressed E-cadherin, a marker of
epithelial cells, and this protein was seen to be in associ-
ation with the plasma membrane, while in AT3 cells E-
cadherin was undetectable by either Western blots or
immunoﬂuorescence (Fig. 1 and data not shown). This
result did not depend on the conﬂuency of cells (data not
shown). When we stained for Vimentin, which is a mes-
enchymal marker, DT cells were uniformly negative, but
AT3 cells showed heterogeneous staining, with about 10%
of the cells showing bright staining (data not shown). A
previous study that included AT3 and DT cell lines and
other lines from the Dunning prostate carcinoma system
found a progressive decrease in keratin and increase in
Vimentin staining from well-differentiated and low-meta-
static (like DT) to anaplastic and highly metastatic lines
(like AT3) [44]. These data and ours are consistent with the
DT and AT3 cells representing two points in the epithelial–
mesenchymal axis.
To further test this idea we carried out en masse gene
expression analysis in DT and AT3 cells. Total RNA was
extracted from three independent cultures of DT and AT3
each and transcript levels were quantiﬁed using the RO27 K
rat spotted arrays 3.0 (Operon, Inc.) (https://www.operon.
com/arrays/OpArray_rat.php). The complete list of gene
products that were overexpresed by[2-fold (P\0.01) is
presented in Supplemental Table 2. DT cells were shown to
express *1,000-fold greater levels of Cingulin, Integrin-ß6
and Zyxin transcripts than did AT3 cells (Table 1). These
gene products have been associated with interactions
between epithelial cells [45]. Several other epithelial plas-
ticity related transcripts, including the RNA for E-cadherin,
werealsoover-representedby*16to*300-foldinDTcells
relative to AT3 cells (Table 1). The expression analysis was
consistent with DT as deﬁning an epithelial-like phenotype
in the plasticity axis. There were, however, some overex-
pressed gene products that are not expected in normal
epithelialcells(e.g.,Mmp9)(italicizedinTable 1).Whereas
we cannot fully explain the increased expression of these
gene products in DT relative to AT3 cells, it is important to
note that DT cells are not normal epithelial cells but rather
transformed cells [36]. Moreover, MMP9 was also reported
to have increased expression in an ‘‘epithelial’’ cell line
derived from transitional cell carcinoma of the bladder [46].
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showed a dramatic signature consistent with EMT: the reg-
ulators Twist and Snail RNAs were both upregulated *280
and *15-fold, respectively, and Vimentin was upregulated
*24-fold (Table 2). This was consistent with results from
detection of Vimentin protein in AT3 cells in culture above
andalsoinAT3tumorsinvivo[29].AsnotedfortheDTcells
therewasatranscriptassociatedwithepithelialplasticity,the
RNA for Syndecan 2, which is not expected in EMT (see
Discussion below). It should be emphasized here that epi-
thelial–mesenchymal differences cannot account for all of
the differences in gene expression between DT and AT3
cells. Nonetheless, the overall gene expression pattern of
transcripts associated with epithelial plasticity suggested
that the transition of the Dunning tumors from DT to AT3
cells involved an EMT.
In order to evaluate the relevance of Dunning model to
human prostate cancer, we compared the gene expression
proﬁles in these cells with that in human prostate tumors
and metastases. In order to do this, we used Gene Set
Enrichment Analysis (GSEA) [33] and compared our data
to that from patient specimens [34]. GSEA is a powerful
Fig. 1 DT cells show high
levels of expression and
predominantly junctional
distribution of E-cadherin
compared to AT3 cells. Overlay
of E-cadherin
immunoﬂuorescence and
Hoechst staining of the same
ﬁelds (left panels) as well as
phase contrast images (right
panels) for both DT and AT3
cells. E-Cadherin antibody is
labeled with AlexaFluor 555
and images were acquired at
2009 magniﬁcation
Table 1 Epithelial plasticity related transcripts overexpressed in DT relative to AT3 cells
Fold AT3/DT Common gene name Genbank (Rat) Description
0.060 CLI; APOJ; SGP2; SGP-2;
SP-40; Trpm2; Trpmb; TRPM-2;
TRPM2B; RATTRPM2B
M16975 Clusterin
0.017 Igfbp7 BC086582 Insulin-like growth factor binding protein 7
0.012 Notch3 AF164486 Notch gene homolog 3
0.008 Cldn4 BC083582 Claudin 4
0.003 Cx26; CXN-26; MGC93804 BC078952 Gap junction membrane channel protein beta 2
0.003 Lisch7; MGC124592 AF119667 Lipolysis stimulated lipoprotein receptor
0.003 C4.4a AJ001043 Ly6/Plaur domain containing 3
0.003 LOC304000 BC086342 Cell adhesion molecule JCAM
0.003 Cdh1 AB017696 Cadherin 1 (E-cadherin)
0.003 MGC93307 BC081757 Growth factor receptor bound protein 7
0.002 Mmp9 U24441 Matrix metallopeptidase 9
0.001 Zyx BF401563 Zyxin
0.001 MGC94023 BC079069 Integrin, beta 6
0.001 Cgn_predicted CK596641 Cingulin (predicted)
614 Clin Exp Metastasis (2008) 25:611–619
123way of matching a deﬁned gene set to the rank order of
another en masse gene expression experiment. The effec-
tiveness of GSEA hinges on the ability to quantify and
visualize the distribution of the deﬁned gene set within the
data of another microarray evaluation. By relying on the
distribution, GSEA is not affected by varying fold change
between cell types. The software determines if genes in a
set (in this case the genes with[2-fold average expression
in AT3 when compared to DT) occur more frequently at
the top or bottom of a list of genes ranked according to
their differential expression across the phenotype of inter-
est (metastatic vs. local prostate cancer). The program
provides an enrichment score (ES) based on a weighted
Kolmogorov–Smirnov statistic and provides a false dis-
covery rate (FDR) based upon the value of the observed ES
compared to the distribution of ES across 1,000 randomly
permutations of phenotypic labels [33].
We found signiﬁcant enrichment for the human meta-
static pattern among genes that were overexpressed C2-
fold in AT3 when compared to DT cells (Enrichment Score
was 0.25, normalized ES of 1.24) and the false discovery
rate was 0.12 (recommended signiﬁcant range\0.25 [33])
(Fig. 2). These data strongly suggest that basic features of
tumor behavior studied in the Dunning prostate adenocar-
cinomas will be observed in human prostate cancers. These
data could also be taken to support the idea that the more
mesenchymal cell line (AT3) was closer in gene expression
pattern to metastases in humans (see Discussion below).
A bichromatic reporter can image splicing differences
in epithelial and mesenchymal cells
We modifed the elegant RG6 bichromatic reporter designed
by Orengo et al. [35] to obtain pRGIIIc, a construct to report
on the inclusion or skipping of the rat FGFR2 exon IIIc
(Fig. 3a). The plasmid pRGIIIc incorporated elements from
previous reporters created in the laboratory [21, 22, 24, 47,
48]. RGIIIc transcripts, like FGFR2 transcripts, preferen-
tially include exon IIIc in AT3 cells (mesenchymal-like)
(Fig. 3b) and this transcript codes for EGFP (see schematic
in Fig. 3a). Indeed, AT3 cells harboring pRGIIIc express
EGFP (Fig. 3c, d). It should be noted that RT-PCR analysis
detected low levels of RGIIIc transcripts that skip exon IIIc
or that use a cryptic site within exon IIIc, which produces
what we called a mini-IIIc exon [48]. Nonetheless, these
levels of transcripts did not result in detectable levels of
RFP (Fig. 3c, d). When we modiﬁed the reporter, we
deleted a nuclear localization signal inserted by Orengo
et al, however, the protein that includes sequences coded by
exon IIIc still localizes to the nucleus of AT3 cells (Fig. 3c).
This serendipitous result was useful when analyzing the
dual expression of the reporter as will be discussed below.
Table 2 Epithelial plasticity related transcripts overexpressed in AT3 relative to DT cells
Fold AT3/DT Common gene name Genbank (Rat) Description
1583.0 Bmp2 Z25868 Bone morphogenetic protein 2
522.1 Igfbp4 CO403206 Insulin-like growth factor binding protein 4
279.5 Twist AF266260 Twist gene homolog 1
138.2 Sema3a X95286 Sema domain, immunoglobulin domain (Ig),
short basic domain, secreted, (semaphorin) 3A
121.0 HSPG BC070890 Syndecan 2
23.8 Vim BC061847 Vimentin
14.9 Sna BC079210 Snail homolog 1
Fig. 2 The Dunning tumor cell lines DT and AT3 recapitulate
differences in gene expression observed during tumor progression in
human prostate cancer. GSEA output showing the distribution of the
gene set with increased expression in the AT3 cells compared to the
DT cells using an a priori established cut off of C2-fold increase in
average expression. Differential enrichment of this gene set was then
tested across a cohort of localized (n = 16) and metastatic (n = 32)
human prostate cancer tumors using previously published data [34]
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preferentially skipped exon IIIc in DT cells (epithelial-like)
(Fig. 3b) and this DIIIc transcript codes for RFP (see
schematic in Fig. 3a). Indeed DT cells harboring pRGIIIc
expressed RFP, which distributes to both the nucleus and
the cytoplasm of these cells, (Fig. 3c, d). Again the analysis
of RNA species suggested that there was low level of
inclusion of IIIc and mini-IIIc exons. It is possible that few
of the DT cells include exon IIIc more efﬁciently and result
EGFP expression (Fig. 3c, d); this result could be taken to
suggest epithelial plasticity among DT cells in culture.
Indeed overlay images indicated that the DT cells
expressing EGFP did not express RFP (data not shown)
(see Discussion). The data shown above demonstrate the
utility of pRGIIIc alternative splicing reporter as a sensor of
epithelial plasticity.
Alternatively spliced bioluminescence reporters can
image mesenchymal–epithelial transitions in lung
metastases
The work above and work previously published [29]
highlighted the utility of ﬂuorescence-based alternative
splicing reporters to detect epithelial–mesenchymal tran-
sitions. These reporters have permitted us to observe these
transitions ex vivo (tumors and lungs were dissected, sec-
tioned and imaged by epiﬂuorescence microscopy). In
order to expand our work to detect these transitions in
animals in vivo we designed bioluminescence alternative
splicing reporters. The design was similar to the ﬂuores-
cence reporters with which we have previously observed
the tumor cells plasticity [29]. The minigene pFFint, which
is used as a control, contains a constitutive intron and was
predicted to express ﬁreﬂy luciferase in both DT and AT3
cells (Fig. 4a). On the other hand pFFIIIcI
2 should produce
luminescence signal only in cells that skip the FGFR2 exon
IIIc (Fig. 4a). Indeed, AT3 cells expressed ﬁreﬂy luciferase
efﬁciently from FFint transcripts but did not from FFIIIcI
2
RNAs (Fig. 4a). On the other hand DT cells expressed
luciferase efﬁciently from FFIIIcI
2 RNAs (Fig. 4b). These
data suggested that these novel reporters could be used to
visualize epithelial status in vivo.
To test this potential, we decided to examine the
behavior of AT3 tumors bearing these bioluminescence
reporters. Whereas AT3 cells in culture and the great
majority of these cells in tumors display a mesenchymal
phenotype, we previously noted that clusters of cells in
tumors and lung metastasis undergo mesenchymal–
epithelial transitions (MET) [29]. We injected one
Copenhagen 2331 rat sc in both ﬂanks with AT3 cells
stably transfected with pFFint and three animals were
injected sc in both ﬂanks with AT3 cells stably transfected
with pFFIIIcI
2. Tumors were left to grow and appearance
of metastasis in lungs was monitored by in vivo lumines-
cence imaging every other day. In all four animals,
luminescence-reporters AT3 cells were mixed with AT3
cells stably expressing EGFP, so metastasis observed with
luminescence could be conﬁrmed at microscopic level.
Fig. 3 Bichromatic ﬂuorescence RGIIIc construct to report on EMT
and MET. (a) Schematic of the dual reporter (adapted from Orengo
et al. [35]). Inclusion of exon IIIc of FGFR2 results in a fusion protein
in frame with EGFP while skipping of this exon results in RFP
expression. (b) RT-PCR analysis of total RNA from AT3 and DT
cells stably transfected with RGIIIc resulted in the expected size
products (446 bp for products that include exon IIIc and 301 bp for
products that skip this exon). The middle-size band was sequenced
and represents a product that includes ‘‘mini IIIc’’, which lacks the
last 50 bases of the IIIc exon due to an alternative 50 splice site we
recently described (see [48]). Lanes are: 1, RT from naı ¨ve cells; 2,
PCR without RT from AT3-RGIIIc or DT-RGIIIc cells; 3 and 4,
duplicates of RT-PCR reactions from AT3-RGIIIc or DT-RGIIIc
cells. (c) Fluorescence and phase-contrast imaging of AT3-RGIIIc
and DT-RGIIIc cells (images were acquired at 2009 magniﬁcation).
(d) Flow cytometric analysis of AT3 and DT cells (left panels) and
AT3-RGIIIc and DT-RGIIIc cells (right panels)
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123Thirteen days following implantation, strong lumines-
cence signal was seen in the two primary tumors of the
FFint animal and much weaker luminescence was detected
in the lungs (Fig. 4c; two images of the same animal
(FFint) are shown in the two panels). Only three of the six
FFIIIcI
2 tumors had detectable luminescence (on both
ﬂanks of animal 02-FFIIIcI
2 and on the left ﬂank of animal
03-FFIIIcI
2). This is consistent with our previous ex vivo
observations using ﬂuorescence reporters [29] and we
interpret the (low level) luminescence in the FFIIIcI
2 pri-
mary tumors as originating in MET foci (Fig. 4c).
Interestingly, the intensity of the signal from the reporters
observed in the lung metastases relative to the signal from
the primary tumors was higher for FFIIIcI
2 tumors
(Fig. 4c). Indeed in the case of the one animal (01-FFII-
IcI
2—Fig. 4c), only cells metastatic to the lung expressed
luciferase, and thus had undergone MET. These observa-
tions suggested that MET was more frequent in metastases
as we had predicted based on our ex vivo analysis [29].
Moreover, these data show that the luminescence reporters
can be used to observe alternative splicing changes in vivo
during tumor progression and metastasis.
EMT and MET transitions have been described before
and are thought to play an important role during develop-
ment, when cells activate or repress different gene
expression programs in order to migrate at a certain point
in time and space and later become stationary [25, 49, 50].
There is an increasing number of reports showing that cells
at the edge of carcinomas or metastatic cells are able to
reactivate EMT and MET programs in order to successfully
complete the metastasis program [28, 49]. Nonetheless,
skepticism still exists in the ﬁeld about the existence of
these transitions during tumor invasion and metastasis,
especially because of the lack of evidence in vivo [51]. In
previous work, we have shown that the AT3 cells, which
have been previously described as mesenchymal-like [38,
52], display surprising plasticity during tumor growth and
metastasis [29]. Using alternative splicing reporters we
observed MET occurring both in tumors (especially near
stroma) and in lung metastasis around blood vessels. The
previous observations were done ex vivo, by excising the
tumors and metastatic lungs and analyzing sections under
epiﬂuorescence microscopy. In this work, to our knowl-
edge, we are the ﬁrst to show that MET associated with
tumor growth and metastasis can be visualized in a living
animal. Using alternatively spliced luciferase reporters that
have a very low signal when cells display a mesenchymal-
like phenotype and high signal when cells turn to a more
epithelial-phenotype we show that it is possible to follow
MET in vivo in living animals. Although we have not ruled
out that a very small population of cells could have tran-
sitioned in the culture dish, and expanded only after
implantation, we believe that the data shown here and our
previously published data are much more likely due to
epithelial transitions occurring post-implantation. Regard-
less, we have developed tools that can be used to study the
contribution of MET to metastasis in vivo in this particular
system. Additionally, here we show the ﬁrst generation of
bichromatic reporters that can sense both EMT and MET.
We propose that Dunning tumor cells (both DT and
AT3) might be in metastable phenotypic states. Indeed the
expression of Mmp9 and other mesenchymal gene products
Fig. 4 Bioluminescence reporters and in vivo bioluminescence
imaging of MET. (a)( Left) Schematic of bioluminescence minigene
reporter constructs pFFIIIcI
2 and pFFint (see Materials and methods).
(Right) Bioluminescence imaging of AT3 cells stably transfected with
the pFFIIIcI
2 and pFFint. (b) Bioluminescence imaging of AT3 cells
stably transfected with pFFint (left), AT3 cells stably transfected with
pFFIIIcI
2 (middle) and DT cells stably transfected with pFFIIIcI
2
(right). Each ﬂask was seeded with 1 million cells the day before
images were acquired. (c) Bioluminescence images of three different
animals having FFIIIcI
2 tumors in both ﬂanks (left animal in the left
panel; left and middle animals in the right panel) and the same animal
with control FFint tumors in both ﬂanks (right animal in both panels)
taken 13 days after subcutaneous injection of tumor cells. The yellow
arrows indicate positions of the ﬂank tumors. The color scales
represent the signal intensities at the surface of the animals in
photons/(cm
2 s steradian). Minimum and maximum thresholds (after
background substraction) are also indicated. In all cases photons were
counted for 120 s. The image on the right was taken 20 min after
injection of luciferin while the image on the left was taken 40 min
after injection
Clin Exp Metastasis (2008) 25:611–619 617
123at higher levels in DT cells than AT3 cells and vice versa
for Syndecan 2 in AT3 cells may reﬂect this metastability.
Indeed the expression of EGFP by a small number of DT
cells transfected with the pRGIIIc bichromatic reporter is
consistent with this idea. We posit that the ability of these
cells to toggle between phenotypic states contributes to
malignancy. Whereas we make our proposal based on a rat
model system for prostate cancer, our comparison of the
Dunning cells with human specimens strongly suggests that
our hypothesis has relevance to human cancers.
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